Results for this period
First quarter1 July 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Sales from large orders from domestic pharmaceutical companies and from domestic academia increased in the life sciences research support services business. The functional materials development support services and biomanufacturing support services businesses declined as they were between clinical trial or joint research projects. Cost of sales declined substantially due to lower purchases of alliance services and an increase in work in progress, while selling, general and administrative expenses were roughly unchanged from the same period of the previous year due to expense reductions at overseas subsidiaries.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2026–30 September 2026 |
| Net Sales | ¥253 million (YoY +31.6%) |
| Operating profit | △4 |
| Ordinary income | △0 |
| Profit attributable to owners of the parent | △3 |
| Net income per share | -¥0.59 |
| Equity ratio | End of the current fiscal period 86.1 / End of previous period 80.2 |
| Total assets | ¥1,974 million |
| Net assets | ¥1,700 million |
| Full-year earnings forecast | Net Sales ¥1,500 million (YoY +5.5%) / Operating profit ¥220 million (YoY +4.8%) / Ordinary income ¥220 million (YoY +6.4%) / Net income ¥170 million |
| Annual Dividend Forecast | ¥18 → ¥18（0.0%） |
| Depreciation and amortization | ¥28,897 thousand |
| Breakdown of extraordinary income (loss) | Current fiscal year Not applicable (total extraordinary gains shown as “-”; no extraordinary losses recorded) / Same period of the previous year Extraordinary Income ¥17,993 thousand |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes Yes (change in the method of calculating tax expenses) / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Material subsequent events | Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 5,919,797 Shares |
| Treasury Shares at Period-End | 542,218 Shares |
| Factors Behind Changes in Business Performance | Sales from large orders from domestic pharmaceutical companies and from domestic academia increased in the life sciences research support services business. The functional materials development support services and biomanufacturing support services businesses declined as they were between clinical trial or joint research projects. Cost of sales declined substantially due to lower purchases of alliance services and an increase in work in progress, while selling, general and administrative expenses were roughly unchanged from the same period of the previous year due to expense reductions at overseas subsidiaries. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales from large orders from domestic pharmaceutical companies and from domestic academia increased in the life sciences research support services business. Cost of sales also declined substantially as work in progress increased due to lower purchases of alliance services and an increase in the order backlog, while expense reductions at overseas subsidiaries contributed to the narrowing of the operating loss.